We estimate that the CEO of Zymeworks Inc. ($ZYME), Kenneth Galbraith, received a compensation of $5,253,616 in 2024. This is an increase of 35.76% from an estimated $3,374,876 in 2023.
These estimates are based on a new DEF14A filing, filed with the SEC on November 10, 2025. Note that parsing errors may occur.
You can track $ZYME on Quiver Quantitative's $ZYME stock dashboard.
$ZYME Stock Insider Trading Activity
$ZYME Stock insiders have traded $ZYME stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ZYME stock by insiders over the last 6 months:
- CAPITAL, LLC ECOR1 has made 2 purchases buying 55,421 shares for an estimated $635,585 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ZYME Stock Hedge Fund Activity
We have seen 88 institutional investors add shares of $ZYME Stock stock to their portfolio, and 90 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ECOR1 CAPITAL, LLC added 5,710,840 shares (+33.1%) to their portfolio in Q2 2025, for an estimated $71,671,042
- BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. removed 2,039,656 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $34,837,324
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 1,420,432 shares (-36.6%) from their portfolio in Q2 2025, for an estimated $17,826,421
- ASSENAGON ASSET MANAGEMENT S.A. added 833,994 shares (+169.2%) to their portfolio in Q3 2025, for an estimated $14,244,617
- BRIDGEWAY CAPITAL MANAGEMENT, LLC removed 766,944 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $9,625,147
- VESTAL POINT CAPITAL, LP added 650,000 shares (+130.0%) to their portfolio in Q2 2025, for an estimated $8,157,500
- REDMILE GROUP, LLC removed 638,318 shares (-13.3%) from their portfolio in Q2 2025, for an estimated $8,010,890
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ZYME Stock Analyst Ratings
Wall Street analysts have issued reports on $ZYME in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B. Riley Securities issued a "Buy" rating on 10/10/2025
- Citigroup issued a "Buy" rating on 08/11/2025
- TD Securities issued a "Buy" rating on 05/20/2025
To track analyst ratings and price targets for $ZYME Stock, check out Quiver Quantitative's $ZYME forecast page.
$ZYME Stock Price Targets
Multiple analysts have issued price targets for $ZYME recently. We have seen 5 analysts offer price targets for $ZYME in the last 6 months, with a median target of $23.0.
Here are some recent targets:
- Eva Fortea Verdejo from Wells Fargo set a target price of $17.0 on 11/07/2025
- Brian Cheng from JP Morgan set a target price of $23.0 on 10/16/2025
- Robert Burns from HC Wainwright & Co. set a target price of $26.0 on 10/14/2025
- Mayank Mamtani from B. Riley Securities set a target price of $30.0 on 10/10/2025
- Yigal Nochomovitz from Citigroup set a target price of $22.0 on 08/11/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
